CTOs on the Move

DynPort Vaccine Company

www.dynport.com

 
DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.dynport.com
  • 64 Thomas Johnson Dr
    Frederick, MD USA 21702
  • Phone: 301.607.5000

Executives

Name Title Contact Details

Similar Companies

Md's Choice Inc

Md's Choice Inc is a Louisville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Esperion

Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren`t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets and is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol.

Dynarex Corporation

Dynarex Corporation is a Orangeburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZO Skin Health

ZO® Skin Health provides a comprehensive range of solutions that will restore skin to a healthy state. From correcting sun damage and pigmentation to acne and aging, ZO® offers a simple, systematic approach to creating and maintaining healthy skin.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.